Nurix Therapeutics’ NX-5948 Secures the EMA’s PRIME Designation for Treating R/R Chronic Lymphocytic Leukemia
Shots:
- The EMA has granted PRIME designation to NX-5948 for adults with r/r chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) treated with at least a BTK or a BCL-2 inhibitor
- NX-5948 is currently being assessed under P-I study for its safety & anti-cancer activity for treating r/r B cell malignancies, with further pivotal studies anticipated in 2025
- NX-5948 (oral) is a small molecule that works by degrading BTK, responsible for growth signaling in B-cell. It has depicted the ability to cross blood-brain barrier in animal models, showing potential for CNS lymphoma & brain diseases; it was also effective in autoimmune disease models, incl. rheumatoid arthritis & multiple sclerosis
Ref: Nurix Therapeutics | Image: Nurix Therapeutics
Related News:- Nurix Reports Positive Results of BTK degraders, NX-5948 and NX-2127 in P-Ia/Ib Trial for the Treatment of Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
